新疆医科大学学报
新疆醫科大學學報
신강의과대학학보
JOURNAL OF XINJIANG MEDICAL UNIVERSITY
2015年
7期
850-854
,共5页
甲状腺微小乳头状癌%Galectin-3%CK19%HBME-1%标志物%免疫组织化学
甲狀腺微小乳頭狀癌%Galectin-3%CK19%HBME-1%標誌物%免疫組織化學
갑상선미소유두상암%Galectin-3%CK19%HBME-1%표지물%면역조직화학
small papillary thyroid carcinoma%Galectin-3%CK19%HBME-1%markers
目的：探讨甲状腺微小乳头状癌中 Galectin-3、CK19和 HBME-1的表达及其临床意义。方法采用免疫组化 Envision 法检测甲状腺微小乳头状癌及甲状腺良性病变伴乳头状增生中 Galectin-3、CK19及 HBME-1的表达，并分析 Galectin-3、CK19及 HBME-1与临床病理的关系。结果CK19的表达定位于胞浆中，CK19甲状腺微小乳头状癌和甲状腺良性病变伴乳头状增生中的阳性表达率分别为92．5％（37／40）和10．0％（4／40），差异有统计学意义。有38例（95．0％）Galectin-3阳性表达，阳性部位定位于细胞膜和细胞质上，呈弥漫性阳性表达。34例（85．0％）样本 HBME-1呈中度阳性及强阳性着色，2例（5．0％）呈弱阳性着色，主要在细胞膜及少部分胞质中表达，阳性表达率为90．0％。17例（42．5％）乳头状癌中同时出现 CK19、HBME-1及 Galectin-3强阳性表达，而良性病变患者未见同时出现 CK19、HBME-1及 Galectin-3的强阳性表达。甲状腺微小乳头状癌中 Galectin-3、CK19及HBME-1的阳性表达率明显高于甲状腺良性病变伴乳头增生，差异有统计学意义。CK19的高表达与性别有关， HBME-1的阳性表达与年龄有关，差异具有统计学意义（P ＜0．05）。结论CK19、HBME-1及 Galectin-3在甲状腺微小癌中的表达明显高于甲状腺良性病变伴乳头状增生，是诊断甲状腺微小乳头状癌的重要标志物，联合检测更能提高甲状腺微小乳头状癌的准确性。
目的：探討甲狀腺微小乳頭狀癌中 Galectin-3、CK19和 HBME-1的錶達及其臨床意義。方法採用免疫組化 Envision 法檢測甲狀腺微小乳頭狀癌及甲狀腺良性病變伴乳頭狀增生中 Galectin-3、CK19及 HBME-1的錶達，併分析 Galectin-3、CK19及 HBME-1與臨床病理的關繫。結果CK19的錶達定位于胞漿中，CK19甲狀腺微小乳頭狀癌和甲狀腺良性病變伴乳頭狀增生中的暘性錶達率分彆為92．5％（37／40）和10．0％（4／40），差異有統計學意義。有38例（95．0％）Galectin-3暘性錶達，暘性部位定位于細胞膜和細胞質上，呈瀰漫性暘性錶達。34例（85．0％）樣本 HBME-1呈中度暘性及彊暘性著色，2例（5．0％）呈弱暘性著色，主要在細胞膜及少部分胞質中錶達，暘性錶達率為90．0％。17例（42．5％）乳頭狀癌中同時齣現 CK19、HBME-1及 Galectin-3彊暘性錶達，而良性病變患者未見同時齣現 CK19、HBME-1及 Galectin-3的彊暘性錶達。甲狀腺微小乳頭狀癌中 Galectin-3、CK19及HBME-1的暘性錶達率明顯高于甲狀腺良性病變伴乳頭增生，差異有統計學意義。CK19的高錶達與性彆有關， HBME-1的暘性錶達與年齡有關，差異具有統計學意義（P ＜0．05）。結論CK19、HBME-1及 Galectin-3在甲狀腺微小癌中的錶達明顯高于甲狀腺良性病變伴乳頭狀增生，是診斷甲狀腺微小乳頭狀癌的重要標誌物，聯閤檢測更能提高甲狀腺微小乳頭狀癌的準確性。
목적：탐토갑상선미소유두상암중 Galectin-3、CK19화 HBME-1적표체급기림상의의。방법채용면역조화 Envision 법검측갑상선미소유두상암급갑상선량성병변반유두상증생중 Galectin-3、CK19급 HBME-1적표체，병분석 Galectin-3、CK19급 HBME-1여림상병리적관계。결과CK19적표체정위우포장중，CK19갑상선미소유두상암화갑상선량성병변반유두상증생중적양성표체솔분별위92．5％（37／40）화10．0％（4／40），차이유통계학의의。유38례（95．0％）Galectin-3양성표체，양성부위정위우세포막화세포질상，정미만성양성표체。34례（85．0％）양본 HBME-1정중도양성급강양성착색，2례（5．0％）정약양성착색，주요재세포막급소부분포질중표체，양성표체솔위90．0％。17례（42．5％）유두상암중동시출현 CK19、HBME-1급 Galectin-3강양성표체，이량성병변환자미견동시출현 CK19、HBME-1급 Galectin-3적강양성표체。갑상선미소유두상암중 Galectin-3、CK19급HBME-1적양성표체솔명현고우갑상선량성병변반유두증생，차이유통계학의의。CK19적고표체여성별유관， HBME-1적양성표체여년령유관，차이구유통계학의의（P ＜0．05）。결론CK19、HBME-1급 Galectin-3재갑상선미소암중적표체명현고우갑상선량성병변반유두상증생，시진단갑상선미소유두상암적중요표지물，연합검측경능제고갑상선미소유두상암적준학성。
Objective To investigate expression and clinical significance of Galectin-3,CK19 and HBME-1 in papillary thyroid microcarcinoma.Methods Envision immunohistochemistry was used to detect the ex-pression of Galectin-3,CK19 and HBME-1 in papillary thyroid microcarcinoma and benign thyroid lesions;and their clinical pathology relationship was analyzed.Results The positive expression rate of CK19 in pa-pillary thyroid microcarcinoma and benign thyroid disease was 92.5%(37/40)and 10.0%(4/40)respective-ly,and the difference was statistically significant.There were 37 cases (92.5%)showed positive staining of Galectin-3,three cases (7.5%)were weakly positive staining.The positive part was at the cell mem-brane and cytoplasm,diffuse positive expression.34(85.0%)cases showed positive staining of HBME-1 and 2 cases (5.0%)were weakly positive staining.The positive expression rate was 90.0%.CK19,HBME-1 and Galectin-3 were all expressed in 17(42.5%)patients with papillary thyroid microcarcinoma,and no simultaneous expression of CK19,HBME-1 and Galectin-3 appeared in patients with benign lesions.The expression of Galectin-3,CK19 and HBME-1 in small papillary thyroid carcinoma was significantly higher than that in benign thyroid lesions with papillary hyperplasia,the difference was statistically significant. High expression of CK19 HBME-1 was related with gender,age,the difference was statistically significant (P <0.05).Conclusion The expression of CK19,HBME-1 and Galectin-3 in papillary thyroid microcarci-noma was significantly higher than that in benign lesions caused by papillary thyroid hyperplasia.The com-bined detection of CK19,HBME-1 and Galectin-3 will further improve the accucacy of papillary thyroid microcarcinoma.
